Cuttsy+Cuttsy’s first EcoVadis rating comes back silver!
July 20, 2022 | Environment, Sustainability, What matters to us
Louise Jones, Sustainability Officer at Cuttsy+Cuttsy celebrates their new silver sustainability rating
Over the past year we have been making practical steps to align Cuttsy+Cuttsy to a more sustainable future. Earlier this month, we completed our first voluntary assessment as part of this goal. EcoVadis is a sustainability ratings provider who partner with companies to supply a globally recognised scorecard and performance improvement tools. The submission required a thorough audit across many of our operations, processes, and carbon footprint.
The results are in and Cuttsy+Cuttsy now rate among the top 25 percent of companies assessed by EcoVadis, scoring us a Silver accreditation. As our first submission, this is slightly mind-blowing.
To say I am over the moon would be an understatement. The team and I have worked incredibly hard, and our commitment to sustainability has clearly been reflected. We are incredibly proud of this score, and we are already working on the objectives to achieve Gold.
We are firm believers in better health for everyone and this cannot be achieved without also considering the health of our planet. This is just the first voluntary disclosure we have conducted this year, there will be plenty more to come. Watch this space.
Cuttsy+Cuttsy are committed to a net zero future, and we will achieve this through accurate carbon disclosures and verifiable science-based targets. We will accomplish this, and I look forward to the day when we announce ‘WE DID IT’.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
A seat at the table: what the EU HTA reforms really ask of patient involvement
The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.
Why faster trials make participant understanding more important than ever
As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.
Older trial participants reject bad design, not technology
Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.
5 key takeaways from the Patient Centricity and Engagement Conference
Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.
It’s time to stop calling adverse events ‘manageable’
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
The solution: Good localisation doesn’t feel translated
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.
Healthcare information is becoming easier to access. Trust isn’t.
Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.
It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment
ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.